SCHEMBL2464650

SCHEMBL2464650

O=Cc1ccc(C=CC(=O)NN(C(=O)O)c2ccc(-c3cccs3)cc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 3/20 0.60
TNFRSF1A P19438 4/20 0.42
LMNA P02545 4/20 0.39
HDAC1 Q13547 3/20 0.39
MAPT P10636 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
RECQL P46063 1/20 0.39
HDAC3 O15379 1/20 0.38
KDM4E B2RXH2 2/20 0.37
ERN1 O75460 1/20 0.37
TP53 P04637 1/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
ALDH1A1 P00352 2/20 0.37
HPGD P15428 2/20 0.37
MEN1 O00255 1/20 0.37
GAA P10253 1/20 0.37
PKM P14618 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2136444 0.85 HDAC2 (0.53) HDAC2TNFRSF1ALMNAHDAC1MAPT
SCHEMBL4794017 0.84 HDAC2 (0.44) HDAC2TNFRSF1AHDAC1HDAC3KDM4E
SCHEMBL2464868 0.82 HDAC2 (0.49) HDAC2TNFRSF1AHDAC1MAPTHDAC3
SCHEMBL2468234 0.82 HDAC2 (0.47) HDAC2TNFRSF1ALMNAHDAC1RECQL
SCHEMBL4579847 0.80 RAB9A (0.52) HDAC2LMNAHDAC1MAPTHDAC3
SCHEMBL4579383 0.77 HDAC2 (0.44) HDAC2LMNAHDAC1MAPTHDAC3
SCHEMBL29898509 0.73 HDAC2 (0.48) HDAC2TNFRSF1AHDAC1MAPTRXFP1
SCHEMBL29898510 0.73 HDAC2 (0.48) HDAC2TNFRSF1AHDAC1MAPTRXFP1
SCHEMBL11827219 0.73 HDAC2 (0.72) HDAC2TNFRSF1AHDAC1MAPTHDAC3
SCHEMBL5471588 0.73 HDAC2 (0.72) HDAC2TNFRSF1AHDAC1MAPTHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2007720-B1 BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC (CA) 2013-12-25 EP disclosed
US-8598168-B2 Inhibitors of histone deacetylase METHYLGENE INC. (CA) 2013-12-03 US disclosed
EP-2367599-A1 INHIBITION OF HDAC2 TO PROMOTE MEMORY Massachusetts Institute of Technology (US) 2011-09-28 EP disclosed
WO-2010065117-A1 INHIBITION OF HDAC2 TO PROMOTE MEMORY MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2010-06-10 WO disclosed
US-20080132503-A1 Inhibitors of Histone Deacetylase METHYLGENE INC. (CA) 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132503-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC3 HDAC2 5/4885TNFRSF1A 3142/4885LMNA 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.